Bicycle Therapeutics plc
BCYC
NASDAQ·Healthcare·Biotechnology·Mkt cap $298.4M
$4.30
▲ +1.42%
P/E
-2.70
Mkt Cap
$298.4M
52-Wk Range
$3.75–$9.16
52-Week Range
$3.75 - $9.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 38.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
+2.4% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BCYC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of -$0.72 vs -$0.58 consensus (-25.1% surprise). Revenue of $629.0K vs $4.2M expected (-85.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-25.1%
Revenue trend · last 2Q
—
-78%
Q1 26
Q2 26
$887.0K
$629.0K
Margins · last 2Q
Gross
100.0%
Profit
-8002.1%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Citi · Jun 3, 2026
vs Industry
How BCYC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.